anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Radiofrequency ablation (RFA) of the medial branch nerve is a widely used therapeutic intervention for facet joint pain. However, denervation of the multifidus muscle is an inevitable consequence of RFA. New ablation techniques with the potential to prevent muscle denervation can be designed using computational simulations. However, depending on the complexity of the model, they could be computationally expensive. As an alternative approach, deep neural networks (DNNs) can be used to predict tissue temperature during RFA procedure. The objective of this paper is to predict the tissue spatial and temporal temperature distributions during RFA using DNNs. First, finite element (FE) models with a range of distances between the probes were run to obtain the temperature readings. The measured temperatures were then used to train the DNNs that predict the spatio-temporal temperature distribution within the tissue. Finally, a separate data obtained from FE simulations were used to test the efficacy of the network. The results presented in this paper demonstrate that the network can achieve an error rate as low as 0.05%, accompanied by a 92% reduction in time compared to FE simulations. The approach proposed in this study will play a major role in the design of new RFA treatments for facet joint pain.
NEW MATERIAL:A complex of a magnetic material and physiologically active substance complex wherein the magnetic substance and the physiologically active substance are combined with each other through a polymer amphiphathic to both water and organic solvents. USE:A carcinostatic agent. PREPARATION:For example, 2,4-bis(O-methoxypolyethylene glycol)-6-chloro-S- triazine is added to a boric acid-buffered aq. soln. contg. an antitumorous substance, asparaginase, separated from Escherichia coli to form polyethylene glycol-asparaginase. The polyethylene glycol-asparaginase is dissolved in water to give an aq. soln., which is then adjusted to 8.0pH with an ammonia water. An aq. soln. contg. ferrous and ferric chloride is dropwise added to the aq. soln. to allow the polyethylene glycol-asparaginase to react with the ferrous and ferric chlorides. After sufficiently dialyzed with water, the reaction soln. is lyophilized to provide the magetic material-asparaginase complex.
PURPOSE: A retrospectively analyze of instability after RSA in terms of aetiology, treatment and final functional outcome.
METHODS: A bicentric retrospective study of 31 patients (mean age 67.6 years; 42-83) treated for RSA instability using RSA Arrow System (FH Orthopedics, Mulhouse, France), mean follow-up 41months (range 12-158). Aetiologies for dislocation were evaluated using a previously described classification system for RSA instability. Actions performed during the Revision Surgeries were analyzed and grouped into five categories. Clinical outcome measures included range of motion, SSV, VAS, Constant-Murley scores, satisfaction level and recurrence of instability.
RESULTS: The most frequent aetiology for RSA instability was loss of compression (18), followed by impingement (8) and loss containment (5). Total RSA revision (bipolar procedure) involving both distalization and lateralization occurred in 13 instances. Isolated distalization through the humerus was performed in ten patients and Isolated lateralization through the glenoid in three patients. Three cases of components exchange due to mechanical failure were noted. Bone graft was used in nine instances. Three patients (10%) suffered recurrent instability following Revision Surgery and required an additional stabilizing procedure. At final follow-up all 31 RSA were reported as stable with a mean VAS of 1.1, SSV 54.5%, constant score 48.3, constant ponderate 74.9%.
CONCLUSION: The management of unstable RSA represent a challenge that can be successfully overcome with a revision surgery with compromised functional results. Loss of compression was the most common cause for primary and recurrent RSA instability that were treated principally with bipolar revisions involving component lateralization and distalization.
Liver transplant patients will be assigned to the liver transplant arm and receive the standard 12-week exercise intervention in the TWP. Specific to the liver arm will be certain PROs and functional fitness measures. The Chronic Liver Disease Questionnaire (CLQD) measures health-related QOL in patients with advanced liver disease and has been previously used in patients awaiting transplant. Liver arm participants will also complete the Liver frailty index, which requires a timed 5 sit-to-stands in addition to the other measures collected for the Fried Frailty Index. Participants in this arm will receive liver-specific exercise and wellness materials to support their behaviour change.
The present invention proposes a kind of hepatitis medicament containing Herba Senecionis Scandentis, belongs to the technical field of Chinese herbal medicine processing.Using Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz., Channa argus, GUANGXIANG rattan, Herba Senecionis Scandentis, Testa sojae atricolor, Folium et Cacumen Artemisiae Halodendri seed and EM original solution etc. are prepared from.Channa argus removing toxic substances is reduced phlegm and internal heat, row water eliminating dampness by diuresis, the yin nourishing of strong sun, the preventing and treating of the most suitable hepatitis, and Testa sojae atricolor yin nourishing suppressing the hyperactive liver compatibility Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz. is inducing diuresis and reducing edema, has anti-inflammatory and antalgic treating the liver and the effect protected the liver, all medicine compatibilities to become the core drug for the treatment of damp-heat syndrome icterohepatitis.Medicine oral administration and externally treatment hepatitis is more beneficial for physical rehabilitation.Prevention effect is definite, inexpensive, draws materials easily, the most popular.
Eligible consenting families (following enrollment) will be provided a secure login code and instructions to access the CNH+ educational modules and to send and receive virtual calls and text messages. Parents will be asked to use CNH+ during their entire NICU stay. To ensure equity, interested families without a personal device to access CNH+ will be offered a study-provided iPad for the duration of their infant's stay. Parents will have access to CNH+ while on the unit and 6 months post-discharge.
Consumers must navigate amongst thousands of non-prescription over-the-counter (OTC) health products accessible online or within the traditional retail space in order to address minor health conditions and aliments. Health product expertise, knowledge, guidance or advice is not always easily accessible. The present invention is an interactive algorithm or decision-tree and database system assisting consumers with the selection of non-prescription over-the-counter health products. The consumer can interact with the invention using an app, website or software by answering closed questions of the algorithm. Invention algorithm employs user symptoms, comorbidities, drug interactions, allergies, sensitivities and preferences. Based on user responses, the algorithm selects optimal OTC product(s) within invention product database to address minor aliment of the patient or user. Invention database provides user with optimal OTC product(s), product description, product reviews, manufacturer website, and/or retail space location in order to facilitate user access to product and minor aliment treatment.
The T-box transcription factor T-bet is known as a master regulator of the T-cell response but its role in malignant B cells has not been sufficiently explored. Here, we conducted single-cell resolved multi-omics analyses of malignant B cells from patients with chronic lymphocytic leukemia (CLL) and studied a CLL mouse model with a genetic knockout of Tbx21. We found that T-bet acts as a tumor suppressor in malignant B cells by decreasing their proliferation rate. NF-κB activity, induced by inflammatory signals provided by the microenvironment, triggered T-bet expression, which affected promoter-proximal and distal chromatin coaccessibility and controlled a specific gene signature by mainly suppressing transcription. Gene set enrichment analysis identified a positive regulation of interferon signaling and negative control of proliferation by T-bet. In line, we showed that T-bet represses cell cycling and is associated with longer overall survival of patients with CLL. Our study uncovered a novel tumor suppressive role of T-bet in malignant B cells via its regulation of inflammatory processes and cell cycling, which has implications for the stratification and therapy of patients with CLL. Linking T-bet activity to inflammation explains the good prognostic role of genetic alterations in the inflammatory signaling pathways in CLL.
A composition suitable for use in the waving of hair comprises an aqueous solution of a mixture of a water-soluble bisulphite and a water-soluble cationic thermosetting resin which is the polymeric reaction product of epichlorohydrin and a polyamide derived from a polyalkylene polyamine containing -CnH2nunits in which n is an integer greater than 1, or a mixture of such polyalkylene polyamines, and diglycolic acid or a C3-C8 saturated aliphatic dicarboxylic acid. The spacing of the secondary amine groups in the polyamide molecule may be increased by replacing up to 60% by weight of the polyalkylene polyamine by an aliphatic diamine, e.g. ethylene diamine, propylenediamine or hexamethylene diamine or a heterocyclic amine, e.g. piperazine.  The polyamide may be reacted with the epichlorohydrin in a mole ratio of epichlorohydrin to secondary amine groups of the polyamide of 0.5:1 to 1.8:1.  The bisulphite may be sodium, potassium, ammonium or ethylamine bisulphite or a corresponding metabisulphite which hydrolyses in the presence of water to yield the bisulphite.  The treating solutions may have a pH of 6.5-7.2 adjusted by the addition of alkali, e.g. sodium hydroxide.ALSO:Hair is waved by treating it while arranged in the desired configuration with an aqueous solution of a water-soluble bisulphite and an aqueous solution of a water-soluble cationic thermosetting resin which is the polymeric reaction product of epichlorohydrin and a polyamide derived from a polyalkylene polyamine containing -CnH2nunits in which n is an integer greater than 1, or a mixture of such polyalkylene polyamines, and diglycolic acid or a C3-C8 saturated aliphatic dicarboxylic acid or with an aqueous solution containing both the bisulphite and the cationic thermosetting resin.  The spacing of the secondary amine groups in the polyamide molecule may be increased by replacing up to 60% by weight of the polyalkylene polyamine by an aliphatic diamine, e.g. ethylene diamine, propylenediamine or hexamethylene diamine or a heterocyclic amine, e.g. piperazine.  The polyamide may be reacted with the epichlorohydrin in a mole ratio of epichlorohydrin to secondary amine groups of the polyamide of 0.5:1 to 1.8:1  The bisulphite may be sodium, potassium, ammonium or ethylamino bisulphite or a corresponding metabisulphite which hydrolyzes in the presence of water to yield the bisulphite.  The treating solutions may have a pH of 6.5 - 7.2 adjusted by the addition of alkali, e.g. sodium hydroxide.  After shampooing the hair may be wound on curlers and treated successively with aqueous solutions of the bisulphite and cationic thermosetting resin or simultaneously with a mixture of the two, or it may be treated with the bisulphite and resin, wound on curlers and again treated with the bisulphite and resin.  Application to the hair may be effected by spraying on an absorbent wad.  The hair may then be left for 30-60 minutes at room temperature or for shorter periods at higher temperatures, e.g. about 38 DEG C., attained by placing a plastic cap over the hair, washed and dried.
Participants will receive double-blind matching placebo from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
Carpal tunnel syndrome (CTS) is the most common peripheral neuropathy with an incidence of 2.7-4%. CTS, resulting from compression of the median nerve in the wrist, clinically progresses with tingling, numbness matching the nerve trace, and motor deficit in the presence of progressive nerve damage. Accordingly, the incidence of neuropathic pain is increasing. In addition to these symptoms mentioned, electro-diagnostic tests are used for diagnostic purposes and to determine the severity of nerve compression, and as a result, there are different types of classification, but most commonly CTS is classified as mild, moderate and severe. This classification is of great importance for the regulation of the follow-up and treatment protocol and making the association of existing complaints with the disease. Studies have shown that approximately 80% of CTS patients wake up at night due to numbness in the hand, resulting in deterioration in sleep quality. Impairment of sleep quality may cause increased sympathetic nervous system activity and awakening of physical and psychological stressors. Deterioration in sleep quality may cause depression and anxiety. Conflicting results have been found in the studies related to these findings. However, no study was found in which daytime sleepiness was evaluated in terms of CTS. The investigators aim in this study is to evaluate the relationship between CTS severity and depression, anxiety, sleep quality and daytime sleepiness. This study;149 patients with a diagnosis of CTS were prospectively included in the study. Electro-diagnostic test results were used to determine the severity of the disease. In this context, Boston CTS rating scale was used to evaluate the functional and symptomatic effects, Pittsburgh sleep quality scale and Epworth sleepiness scale were used to evaluate sleep quality and daytime sleepiness, and pain DETECT questionnaire was used to evaluate pain type.
Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take histidine and beta-alanine supplementation.
Randomised participants will be instructed to walk 6,000 steps per day and throughout the day for 12 weeks. Step counts will be monitored by an issued pedometer. A 12 week paper diary will be provided for daily recording of step counts.
Depression is a serious illness that affects a person's mood, thoughts, and physical well-being. Common symptoms of depression include persistent feelings of anxiety, guilt, or hopelessness; irregular sleep and appetite patterns; lethargy; disinterest in previously enjoyed activities; excessive irritability and restlessness; suicidal thoughts; and inability to concentrate. Depression often occurs in the presence of one or more other disorders. For example, depression is reported to be at a higher rate in people with chronic obstructive pulmonary disease (COPD) than in the general population. COPD is a disease in which the lungs are damaged, making it difficult to breathe. Symptoms most commonly include chronic coughing and shortness of breath. A primary cause of COPD is cigarette smoking. Following a prescribed treatment plan is important for managing COPD. Unfortunately, people with COPD often do not adhere to their treatment plans. Being depressed makes adherence even more difficult. This study will evaluate the effectiveness of problem-solving therapy integrated with adherence-enhanced procedures (PSA) in treating older people with major depression and COPD.

Participants in this open label study will be randomly assigned to one of two groups: PSA or PID-C. In PSA, a therapist will teach participants problem-solving strategies focusing on treatment adherence, depressive symptoms, and disability. Participants will learn behaviors and solutions to help cope with these problems. In PID-C, a therapist will teach participants to identify obstacles to treatment adherence and to discover ways to overcome them. The treatment sessions for both groups will be initiated at the inpatient Pulmonary Unit of Burke Rehabilitation Hospital and will continue in the participants' homes. All participants will receive two treatment sessions during hospitalization, eight weekly sessions following discharge, and four monthly sessions after that. While hospitalized at Burke, participants will also undergo an assessment interview for 1.5 hours and another interview for 20 minutes 2 weeks following the initial assessment. Interviews lasting 1.5 hours will also occur in the homes of the participants at Weeks 10, 14, and 26 after discharge from Burke. All assessments will focus on depression severity, level of general functioning, and COPD treatment adherence.
A system and method for determining an optimal combination drug product for a particular patient includes a processor that receives patient information and determines an optimal combination drug product based on the received information. A system which can provide information regarding predicted events or pathologies based on received patient information and guidance on subsequent steps to ameliorate, treat or intervent. A drug production device includes a plurality of drug containers, each of which are coupled to a drug dispensing channel. A controller controls the dispensing of drug through each channel, and a combination drug product is produced from the dispensed drugs. A combination drug product includes a plurality of discrete units of a first drug, and a plurality of discrete units of a second drug.;  A transdermal patch includes a plurality of drug compartments, each containing a quantity of drug product, and a controller for controlling the release of drugs from each compartment. Feedback loop elements can enable iterations to optimized personalized doses.
The efficacy and safety of TARCEVA in combination with gemcitabine as a first-line treatment was assessed in a randomized, double blind, placebo-controlled trial in 569 patients with locally advanced, unresectable or metastatic pancreatic cancer. Patients were randomized 1:1 to receive TARCEVA (100 mg or 150 mg) or placebo once daily on a continuous schedule plus gemcitabine IV (1000 mg/m2, Cycle 1 - Days 1, 8, 15, 22, 29, 36 and 43 of an 8 week cycle; Cycle 2 and subsequent cycles - Days 1, 8 and 15 of a 4 week cycle [the approved dose and schedule for pancreatic cancer, see the gemcitabine package insert]). TARCEVA or placebo was taken orally once daily until disease progression or unacceptable toxicity. The primary endpoint was survival. Secondary endpoints included response rate, and progression-free survival (PFS). Duration of response was also examined. The study was conducted in 18 countries. A total of 285 patients were randomized to receive gemcitabine plus TARCEVA (261 patients in the 100 mg cohort and 24 patients in the 150 mg cohort) and 284 patients were randomized to receive gemcitabine plus placebo (260 patients in the 100 mg cohort and 24 patients in the 150 mg cohort). Too few patients were treated in the 150 mg cohort to draw conclusions.

Table 6 summarizes the demographic and disease characteristics of the study population that was randomized to receive 100 mg of TARCEVA plus gemcitabine or placebo plus gemcitabine. Baseline demographic and disease characteristics of the patients were similar between the 2 treatment groups, except for a slightly larger proportion of females in the TARCEVA arm (51%) compared with the placebo arm (44%). The median time from initial diagnosis to randomization was approximately 1.0 month. Most patients presented with metastatic disease at study entry as the initial manifestation of pancreatic cancer.

The results of the study are shown in Table 7. 

Survival was evaluated in the intent-to-treat population. Figure 2 depicts the Kaplan-Meier curves for overall survival in the 100 mg cohort. The primary survival and PFS analyses were two-sided Log-Rank tests stratified by ECOG performance status and extent of disease.

Note: HR is from Cox regression model with the following covariates: ECOG performance status and extent of disease. P-value is from two-sided Log-Rank test stratified by ECOG performance status and extent of disease.
A mixture of an aqueous solution, essential oils and mechanically extracted kelp cytoplasm results in an emulsion with cosmetic and therapeutic properties. The preparation may be used on human and animal hair or skin. The moisturizing properties of the kelp cytoplasm provide the aqueous solution to the hair (keratin) which is absorbed, causing the hair to swell, and become heavier and more pliable. The alginate gels and oils in the emulsion coat the hair strands to reduce breakage and splitting and add weight to the strand. The preparation dries with gel capsules, which release moisture over time for a long-lasting effect. The preparation also provides nutrients, gel and moisture to the skin and fills micro cracks in the keratin layer of dry, chapped skin. The preparation seals off the cracks from the environment while trapping moisture pockets. This provides an environment conducive for healing.
BACKGROUND: Despite substantial progress in reducing the global burden of chronic obstructive pulmonary disease (COPD), traditional methods to promote understanding and management of COPD are insufficient. We developed an innovative model based on the internet of things (IoT) for screening and management of COPD in primary healthcare (PHC).
METHODS: Electronic questionnaire and IoT-based spirometer were used to screen residents. We defined individuals with a questionnaire score of 16 or higher as high-risk population, COPD was diagnosed according to 2021 Global Initiative for COPD (Global Initiative for Chronic Obstructive Lung Disease) criteria. High-risk individuals and COPD identified through the screening were included in the COPD PHC cohort study, which is a prospective, longitudinal observational study. We provide an overall description of the study's design framework and baseline data of participants.
RESULTS: Between November 2021 and March 2023, 162 263 individuals aged over 18 from 18 cities in China were screened, of those 43 279 high-risk individuals and 6902 patients with COPD were enrolled in the cohort study. In the high-risk population, the proportion of smokers was higher than that in the screened population (57.6% vs 31.4%), the proportion of males was higher than females (71.1% vs 28.9%) and in people underweight than normal weight (57.1% vs 32.0%). The number of high-risk individuals increased with age, particularly after 50 years old (χ2=37 239.9, p<0.001). Female patients are more common exposed to household biofuels (χ2=72.684, p<0.05). The majority of patients have severe respiratory symptoms, indicated by a CAT score of ≥10 (85.8%) or an Modified Medical Research Council Dyspnoea Scale score of ≥2 (65.5%).
CONCLUSION: Strategy based on IoT model help improve the detection rate of COPD in PHC. This cohort study has established a large clinical database that encompasses a wide range of demographic and relevant data of COPD and will provide invaluable resources for future research.
Middle dose of STSP-0902 ophthalmic solution to study eye. Three times daily for a total of 8 days.